3. Results
cough, diarrhoea, hoarseness, scratchy throat
ADVERSE EVENTS
Four hundred and twenty-six participants enrolled in the study, with 398 participants completing full trial requirements. There were 19 withdrawals in the active group and 9 in the placebo group. The Levagen+ group reported four adverse events (diarrhoea, A total of 87 participants experienced at least one URTI during the study, with a total of 103 URTI episodes recorded. The Levagen+ group reported significantly fewer URTI episodes (39 and 64, respectively; The number of sick days per episode ranged from 2 to 14 days in both groups, with no significant difference in the median number of sick days between the two groups. For participants reporting a URTI, the Levagen+ group reported a significantly lower severity score for scratchy throat and cough, with hoarseness and the ability to breathe easily trending towards significance (Comparisons between groups for the number of people reporting a specific symptom from the WURSS-24 showed no significant difference between groups for any outcome measure (There was no significant difference between groups for the number of people who thought they were on the active product (83 vs. 92 in the Levagen+ and placebo groups, respectively). Similarly, no significant difference was observed in the number of people willing to take the study product again (80 vs. 91 in the Levagen+ and placebo groups, respectively).